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Kids Swallowing Pennies
Doctors at Duke University
Medical Center in Durham,
North Carolina, have
learned that a penny
saved isn't always a
good thing, particu-
larly if that penny
was minted after
1982. A team of
doctors found that
children who swal-
low post-1982 pen-
nies may develop
stomach ulcers if the
coins become lodged in
their digestive tracts. More
than 21,000 children visited the
emergency room in 1997 after swallowing
coins.
In a presentation at the 84th annual
meeting of the Radiological Society of
North America, held 29 November-4
December 1998, Sara M. O'Hara, an
assistant professor ofpediatric radiology at
Duke, and colleagues described the case of
a two-year-old boy who was brought to
the emergency room complaining ofstom-
achache. Upon taking an initial X ray of
the boy's abdomen, O'Hara spotted a
small, metal disc in his stomach. A follow-
up X ray four days later indicated that the
item appeared to be dissolving.
Once the object was removed from the
boy's stomach with an endoscope, it was
found to be a 1989 penny, riddled with
holes. Intrigued, O'Hara and colleagues
Lane F. Donnelly, William H. Briner, and
George S. Bissett of the Duke radiology
department and Emil M. Chuang of the
Duke pediatrics department decided to
investigate what had happened to the penny.
O'Hara visited the U.S. Mint Web site
to find out what pennies are made of. She
learned that pennies minted after 1982 are
composed largely of zinc. O'Hara checked
with a staff chemist, who told her that the
chemical reaction between zinc and stomach
acid (hydrochloric acid) is similar to that in
wet cell batteries and would likely be caustic
to the stomach lining. Apparently, when the
penny became trapped in the boy's stomach,
its zinc base reacted with stomach acid to
produce hydrogen gas and zinc chloride (a
major ingredient in the smoke from smoke
bombs). According to O'Hara, this chemical
reaction dissolved the zinc base of the coin,
creating holes in the coin and ulcerations in
the stomach lining. Other U.S. coins, which
are made mostly of nickel, would not be
expected to present this problem.
Zinc is an important nutri-
ent that aids in maintaining
a healthy immune system
and promotes wound
healing and reproduc-
tive health. Too much
zinc can result in
ulcers, anemia, and
damage to the kidneys,
liver, and bone mar-
row. But it takes much
more than the recom-
mended daily dose of
12-15 mg to cause adverse
_ health effects. Large doses of
dietary zinc (120-150 mg) can cause
stomach cramps, nausea, and vomiting.
Taking in high levels of zinc over several
months may cause anemia, pancreatic dam-
age, and decreased levels of high-density
lipoprotein ("good") cholesterol.
While one penny is not typically
enough to cause such systemic damage in a
child, it can spell trouble for a pet. For
children, the more likely danger would be
if the penny became lodged in the stom-
ach, where it would effectively act as a
small blowtorch, eating away at the stom-
ach lining. According to Dr. O'Hara, coins
rarely cause bowel obstruction, and there
are no other known prob-
lems associated with a coin
lodged in the gut. The major
hazard associated with chil-
dren swallowing coins is that
the child might choke.
Children and pets who
swallow pennies should be
monitored to ensure the
coin passes. If it doesn't
show up within two days or
ifthe swallower starts having
stomach problems, the child
or animal should be taken to
the doctor immediately.
The Lincoln penny was
introduced in 1959 and
minted until 1982, when the
rising price of copper dictat-
ed a change in its makeup.
The penny's composition
was changed from an alloy of
95% copper and 5% tin and
zinc to 97.5% zinc and 2.5%
copper. Several billion new
pennies are minted each year
in the United States.
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Captured! The IgE receptor, shown
front and back above, is composed
of protein atoms (white) and car-
bohydrates (blue). The IgE anti-
body binds to the top point of the
inverted V shape.
O'Hara's findings at the U.S. Mint
prompted her and her colleagues to con-
duct an experiment. They exposed 18
pennies, 6 minted before 1982 and 12
minted after, to postprandial concentra-
tions ofstomach acid. The post-1982 pen-
nies began eroding immediately; perfora-
tions had appeared by the second day.
Within 7 days, the post-1982 pennies had
decreased in weight by 5-8% and were
lacy with holes, while the pre-1982 pen-
nies were unchanged.
The Duke researchers' findings may be
pertinent to nations besides the United
States. In 1997, the Royal Canadian Mint
began producing a 98.4% zinc version of
its formerly bronze penny. Pierre Morin,
communications advisor for the Royal
Canadian Mint, says, "We are interested
in reviewing this study once the results
become available because our one-cent
penny has changed to a copper-plated zinc
coin. We want to review their methodolo-
gy as well as their results."
Allergy Receptor Pictured
For many people, the rites of spring have
historically involved stocking up on plenty
of antihistamines and tissue, but that may
not be the case in the future. Researchers at
Northwestern University in Chicago and
Harvard Medical School
in Boston have deter-
mined the precise shape
ofthe receptor protein for
immunoglobin E (IgE),
the antibody that is
responsible for the spring-
time sniffles and other
allergic symptoms that
afflict some 20% of the
U.S. population. This
may be the first step
toward developing an
allergy medication that
stops the allergic response
before it happens, rather
than merely treating the
symptoms.
The study was report-
ed in the 23 December
1998 issue of Cell.
Theodore S. Jardetzky, an
assistant professor in the
Department of Biochem-
istry, Molecular Biology,
and Cell Biology at
Northwestern, was the
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principal investigator for the team. His col-
laborators were Jean-Pierre Kinet, a profes-
sor of pathology at Harvard Medical
School who first cloned the gene for the
IgE receptor in 1986, and Scott Garman, a
postdoctoral fellow in the Northwestern
Department of Biochemistry, Molecular
Biology, and Cell Biology.
About 50 million people in the United
States have some form of allergy. Many
allergies, such as hay fever and eczema, are
more inconvenient than life-threatening,
but some allergic responses, such as ana-
phylaxis, can result in death. Allergies are
also strongly suspected ofplaying a role in
asthma. According to the National
Institute of Allergy and Infectious
Diseases, 90% of asthmatic children and
50% ofasthmatic adults also have allergies.
According to the Centers for Disease
Control and Prevention, asthma accounts
for almost 500,000 hospitalizations each
year and is the foremost reason that chil-
dren miss school. And the problem is
growing-asthma prevalence in the United
States is expected to rise by 5% each year.
Allergic responses are mediated by IgE,
which is one of five classes of antibodies.
As IgE circulates through the blood and
the lymph, it binds to receptors found on
the surface of mast cells (a type of white
blood cell). There, IgE acts as an antenna,
patrolling its airspace for allergens. When
an antibody picks up the signal ofa nearby
allergen, the mast cell responds by releasing
histamine and other powerful chemicals
that cause an inflammatory response in
surrounding tissues.
Mast cells are found throughout the
body but are most highly concentrated in
tissues that are exposed to the outside
world, such as the skin and nasal and lung
linings. So when an allergic response
occurs, those tissues are most likely to be
affected, resulting in the rashes, welts,
runny noses, and watery eyes traditionally
associated with allergies.
The IgE receptor had previously defied
imaging because it has a heterogenous
sugar coating that solubilizes the receptor
and prevents it from crystallizing into a
structure that can be examined through X-
ray diffraction. To counteract this prob-
lem, the scientists expressed the human
1gE receptor gene in cultured insect cells
from the cabbage looper and the fall army-
worm, which attach fewer sugars to the
molecule. Next, they applied a technique
called multiple isomorphous replacement,
in which IgE receptor crystals were soaked
in one of two solutions containing either
gold or platinum. The large, heavy atoms
of the metals were absorbed into the crys-
tals, adding mass in the form of electrons
to the receptor at key points and making it
possible to calculate its image. According
to Jardetzky, by comparing data that corre-
spond to the receptor by itself to another
set ofdata that reflects the changes effected
by the binding ofone ofthese heavy metals
to the receptor, the researchers can calcu-
late the structure ofthe receptor.
The researchers then used the very high
intensity X rays of the Advanced Photon
Source at Argonne National Laboratory in
Illinois to scrutinize the IgE crystals. The
Advanced Photon Source is a synchrotron,
which uses magnetic fields to maintain
charged particles in an orbit. The orbiting
particles give off energy in the form of X
rays. Special detectors measure the X rays
as they bounce off the crystal being ana-
lyzed, and computers convert the data into
an image ofthe crystal.
The researchers found that the receptor
has an inverted "V" shape. At one end of
the V is a spike that attaches the receptor to
the cell membrane. The IgE antibody binds
at the upward-pointing elbow of the V
shape. Jardetzky and colleagues are current-
ly investigating several potential inhibitors
and are working on capturing an image of
Toxic Toys
The controversy about the safety of children's toys continues to play out in the scientific commu-
nity and the media. Not only are there concerns about pesticides accumulating on toys, there is
also fear that some of the chemicals used to manufacture
toys may be posing risks to children's health. Phthalates, XI
chemicals that are added to polyvinyl chloride (PVC)
polymers to create flexible plastics, are receiving most of
the attention. Phthalates are used in products such as
shower curtains, raincoats, balls, squeeze toys, and
medical devices such as tubing and IV bags.
Studies in the 196os detected phthalates in biological
samples, indicating that the chemicals leach out of PVC
plastics. The NIEHS and the National Toxicology Program
(NTP) began studying phthalates following a 1970S dis-
covery that blood stored in PVC plastic bags that was
used for transfusions contained measurable concentra-
tions ofphthalates, and that the chemicals were found in
the organs of humans who had received transfusions.
Initially, the most widely studied phthalate was the
commonly used di(2-ethylhexyl) phthalate (DEHP). In
1982, NTP studies showed that DEHP induced a strong
liver tumor response in rats and mice. Since the 198os,
the NIEHS and the NTP have conducted carcinogenicity
studies on four other phthalates, which were not found _
to cause cancer. They have also conducted reproductive
and developmental toxicity testing on 12 phthalates and
found that toxicity varies widely among the class.
In response to the finding of DEHP's carcinogenicity and to additional findings suggesting
that DEHP may be toxic to the reproductive system, U.S. toy makers agreed in 1986 to limit the
concentration of the chemical in teethers, pacifiers, and squeeze toys to 3%. Many toy makers
began substituting diisononyl phthalate (DINP) for DEHP in these products. However, the envi-
ronmental advocacy group Greenpeace released a study in December 1998 claiming that tests it
had conducted found DEHP levels of 6-44% by weight in a variety of other children's products
that are likely to be placed in the child's mouth, such as plastic bibs. In the controversy that
continues to rage about the risks posed to children by phthalates in toys, a major point of con-
tention is the amount of phthalates that leaches out of toys and into children's mouths.
In the first study to examine the amount of a phthalate that migrates out of children's prod-
ucts, the U.S. Consumer Product Safety Commission examined 31 different products containing
DINP. At high doses in industry-sponsored studies, DINP has been linked with liver tumors and
has been shown to cause damage to the liver, kidney, and other organs in mice and rats. The
results, published in December 1998, also indicate that the amount of DINP ingested by children
is well below harmful levels. The commission concluded that few, if any, children are at risk for
toy-related DINP exposures and therefore did not recommend a ban on products containing the
chemical. However, at the commission's request, go% of manufacturers agreed to remove
phthalates from soft rattles and teethers by early I999. According to Greenpeace, Austria,
Denmark, Finland, Greece, Norway, and Sweden have also banned or taken steps to ban phtha-
lates in toys for children under the age ofthree years due to fears about infant exposure.
The Clinton administration has asked the NIEHS and the NTP to continue studying phtha-
lates. The new NTP Center for the Evaluation of Risks to Human Reproduction announced in April
that its first review will look at reproductive risks to plastics workers and consumers from seven
phthalates, including DEHP and DINP, that arewidely used in consumerproducts.
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IgE bound to its receptor. "It may be more
fruitful for drug development ifwe can get
a picture ofthis 'lock and key' mechanism,"
says Jardetzky. "From that, it may emerge
that it is better to design an inhibitor for
the antibody than for the receptor."
Because allergic responses result only
from IgE binding to the IgE receptor, ther-
apeutic strategies aimed at inhibiting
IgE-receptor interactions could provide a
single treatment to fight multiple condi-
tions such as asthma and sinusitis. The
researchers believe that blocking the IgE
receptor from binding the IgE antibody
will short-circuit the allergy cycle.
Because the IgE-receptor interaction
controls only the allergy branch of the
body's immune response, it could be
inhibited without compromising the entire
immune response, says Kinet. The IgE
receptor is thought to play some as-yet
undefined role in immunity to parasitic
infections. Jardetzky allows that inhibition
of the IgE-receptor interaction may result
in susceptibility to parasitic infections, par-
ticularly in developing nations, where such
diseases are endemic. However, notes
Kinet, IgE is not the only natural defense
the body has against parasites. The advan-
tages offered by such an inhibitor, he says,
would far outweigh the disadvantages.
Safer Drugs for Children
When prescribing drugs for children, pedia-
tricians must often resort to guess-
work in determining the appropriate
dose as well as in assessing the effec-
tiveness of most pharmaceuticals
currently on the market. While
drug testing on humans has been
required by the Food and Drug
Administration (FDA) since the
1960s, an overwhelming majority
ofthe testing has been conducted
on adults. As of 1 April 1999,
however, the FDA is requiring
drug manufacturers to provide
sufficient data and labeling on
the safe use ofdrugs in children.
"Pediatricians and other
health care providers will now
have more specific dosing infor-
mation based on scientific evi-
dence," said First Lady Hillary
Rodham Clinton in an FDA press
release announcing the regulation.
"This will make prescribing medica-
tion for children safer and may also
lessen the number ofside effects."
In 1994, the FDA issued a regula-
tion that simplified the pediatric data
required to obtain pediatric labeling in
order to encourage drug manufacturers to
voluntarily submit such data. The effort was
unsuccessful, and about 75% ofdrugs cur-
rently on the market still lack adequate
pediatric labeling.
In 1997, Congress passed the Food and
Drug Administration Modernization Act
and established an incentive-six months of
protected market exclusivity-for manufac-
turers to conduct tests on the effects of
drugs frequently used in children. The act's
provision for exclusivity is applicable until
2002. "That exclusivity solves some of the
missing information problem," says Diane
Murphy, associate director for pediatrics at
the FDA, "but it doesn't apply to products
that don't have a patent."
The FDA issued a regulation in
November 1998 (which became effective
last April) that requires manufacturers to
assess the safety and effectiveness ofall drugs
that are therapeutically important or com-
monly prescribed for children. The new rule
also requires that some drugs already on the
market be tested ifthey are commonly pre-
scribed for use in children and ifthe absence
of adequate labeling could pose significant
risks to children.
In some cases, pediatric data can be sub-
mitted to the FDA after a new drug has
been approved, especially if the FDA has
safety concerns about testing the drug on
children. "We are not going to hold up a
therapy for adults just because we don't
have all the information for children,"
Murphy says. Deferrals for pediatric testing
3
EnuigsfeyNwFA euain wileur
tetn of soedusfrusycide
may be granted in such cases.
The pediatric data requirement can be
waived entirely ifthe product does not pro-
vide a meaningful therapeutic benefit over
existing treatments and is not likely to be
used in more than 50,000 pediatric
patients. Waivers may also be granted for
products that are likely to be unsafe or inef-
fective in pediatric patients (the assumption
being that they will not be prescribed for
children), if pediatric studies are impracti-
cal, or if reasonable efforts to develop a
pediatric formulation have failed.
As for concerns about testing drugs on
children, Robert Ward, a professor ofpedi-
atrics at the University ofUtah in Salt Lake
City and chair ofthe American Academy of
Pediatrics Committee on Drugs, says there
is extensive literature on how to study drugs
in children. Ward says there is a general
consensus that the metabolism and safety of
a drug should be demonstrated in adults
before being tested in children. The main
issue to remember about pediatric drug test-
ing, he says, is that it comes down to a
choice of giving a child a drug under care-
fully controlled study conditions, or possi-
bly giving a child a drug that has not been
thoroughly tested in children.
There is more at issue than children's
health. The FDA estimates that pediatric
testing will cost less than 1% of the total
spent to develop a new drug, or less than
$50 million a year for all pediatric testing.
However, health care savings due to better
drug treatments for children are estimated
to be $100 million annually.
The National Pharmaceutical Alliance
and the Generic Drug Industry Association
filed a lawsuit in federal court on 19
February 1999 opposing the FDA's inter-
pretation ofthe exclusivity extensions in the
act and requesting that the FDA be stopped
from enforcing the rules.
The industry is arguing that the FDA
has expanded the exclusivity to all forms of
a particular drug, not just the form or forms
used in children. The provision was intend-
ed as an incentive, says Michael Hinckle, an
attorney representing the generic industry,
but the way that the FDA has interpreted it
has resulted in a windfall for brand name
pharmaceutical companies. "This broad
interpretation will cause considerable hard-
ship to the generic industry," Hinckle says.
The American Academy of Pediatrics
filed to intervene in the lawsuit and argue
on behalf of children, but the motion was
denied. "In 1968, the lack of studies on
children was first pointed out," says Ward;
this lack of data remains today. "There is
finally some movement," he says, "and the
generics are potentially going to stop that
process.
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